Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
The COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates will now be tested in a Phase 2 trial, according to Novavax, Inc., a biotechnology company committed to creating and marketing next-generation vaccines for critical infectious diseases. The CIC and influenza…